Limonin stabilises SIRT6 by activating USP10 in cardiac hypertrophy

Li‐Bo Liu,Si‐Hui Huang,Hong‐Liang Qiu,Xian‐Feng Cen,Ying‐Ying Guo,Dan Li,Yu‐Lan Ma,Man Xu,Qi‐Zhu Tang
DOI: https://doi.org/10.1111/bph.15899
IF: 7.3
2022-06-22
British Journal of Pharmacology
Abstract:Background and Purpose Limonin, a natural tetracyclic triterpenoid extract, exerts extensive pharmacological effects; however, its role in cardiac hypertrophy remains to be elucidated. We investigated the beneficial effects of limonin on cardiac hypertrophy and explored the potential mechanisms. Experimental Approach C57/BL6 male mice were subjected to aortic banding (AB) surgery and neonatal rat cardiac myocytes (NRCMs) were stimulated with phenylephrine (PE) to evaluate the effects of limonin on cardiac hypertrophy. Key Results Limonin markedly improved the cardiac function and heart weight in AB operation mice. In addition, limonin‐treated mice and NRCMs produced fewer cardiac hypertrophy markers than those treated with the vehicle in hypertrophic groups. Sustained AB‐ or PE‐stimulation impaired cardiac sirtuin 6 (SIRT6) protein levels, which were partially rescued by limonin and subsequently enhanced the activity of PPARα, and Sirt6 siRNA inhibited the anti‐hypertrophic effects of limonin in vitro. Interestingly, limonin did not influence Sirt6 mRNA levels, but controlled its ubiquitin levels. Thus, the protein biosynthesis inhibitor, cycloheximide (CHX), and proteasome inhibitor, MG‐132, were used to determine SIRT6 protein expression levels. Under PE stimulation, limonin increased SIRT6 protein levels in the presence of CHX, but it didn't influence SIRT6 expression in the presence of MG‐132, suggesting that limonin promotes SIRT6 abundance by inhibiting its ubiquitination degradation. Furthermore, limonin inhibited the degradation of SIRT6 by activating ubiquitin‐specific peptidase (Cuspidi et al.)‐10, while USP10 siRNA abrogated the beneficial effects of limonin. Conclusion and Implications Limonin mediates the ubiquitination and degradation of SIRT6 by activating USP10, providing an attractive therapeutic target for cardiac hypertrophy.
pharmacology & pharmacy
What problem does this paper attempt to address?